Press release
Angio-immunoblastic T-Cell Lymphoma (AITL) Market Expected to Witness Significant Growth Through 2036, Driven by Advancing Targeted Therapies, Improving Diagnosis, and Expanding Treatment Landscape | DelveInsight
DelveInsight's "Angio-immunoblastic T-Cell Lymphoma (AITL) Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive assessment of disease epidemiology, current treatment practices, marketed and emerging therapies, market trends, pricing analysis, therapy uptake, reimbursement landscape, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also evaluates patient burden, competitive intelligence, key opinion leader perspectives, and commercial opportunities expected to influence the AITL market through 2036.
The report further presents detailed insights into historical and forecasted market performance, epidemiological trends, treatment algorithms, patient journey, unmet needs, SWOT analysis, pricing dynamics, and the evolving competitive landscape, enabling pharmaceutical and biotechnology companies to make informed strategic decisions.
To know more about the Angio-immunoblastic T-Cell Lymphoma (AITL) market, epidemiology, and forecast, Click here:
https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Key Takeaways from the Angio-immunoblastic T-Cell Lymphoma (AITL) Market Report
• The Angio-immunoblastic T-Cell Lymphoma (AITL) market is expected to expand steadily across the 7MM during the forecast period (2026-2036), supported by increasing diagnosis, improved molecular characterization, and growing adoption of targeted treatment approaches.
• CHOP-based chemotherapy remains the standard first-line treatment, while ADCETRIS (brentuximab vedotin) is currently the only FDA-approved first-line regimen used in combination with chemotherapy for adults with previously untreated CD30-expressing AITL, reflecting the limited availability of approved frontline therapies.
• Approved therapies across the 7MM include ADCETRIS (brentuximab vedotin), BELEODAQ (belinostat), EZHARMIA (tazemetostat), FOLOTYN/DIFOLTA (pralatrexate), and ISTODAX (romidepsin), while emerging therapies are expected to significantly enhance future treatment options.
• Promising late-stage pipeline candidates include Lacutamab (Innate Pharma), Linperlisib (Shanghai YingLi Pharmaceutical), Duvelisib (Secura Bio), and GFH009 (GenFleet Therapeutics), highlighting continued innovation in the AITL therapeutic landscape.
• According to DelveInsight, the AITL treatment landscape is expected to undergo significant transformation between 2026 and 2036, supported by targeted agents and biomarker-driven therapies that are anticipated to improve clinical outcomes in both frontline and relapsed/refractory settings.
Angio-immunoblastic T-Cell Lymphoma (AITL) Competitive Landscape
The Angio-immunoblastic T-Cell Lymphoma (AITL) treatment landscape continues to evolve with increasing adoption of targeted therapies and biomarker-driven treatment strategies. Current management primarily relies on anthracycline-based chemotherapy regimens, including CHOP and CHOEP, followed by stem cell transplantation in eligible patients. Approved therapies for relapsed/refractory disease include ADCETRIS (brentuximab vedotin), BELEODAQ (belinostat), EZHARMIA (tazemetostat), FOLOTYN/DIFOLTA (pralatrexate), and ISTODAX (romidepsin). However, durable responses remain limited, highlighting the need for more effective targeted therapies.
Leading companies advancing the AITL pipeline include Innate Pharma, Shanghai YingLi Pharmaceutical, Secura Bio, GenFleet Therapeutics, and others developing innovative therapies for relapsed or refractory disease.
Lacutamab (IPH4102): Innate Pharma
Lacutamab (IPH4102) is a first-in-class humanized monoclonal antibody targeting KIR3DL2, a receptor selectively expressed on malignant T cells. The therapy has demonstrated encouraging anti-tumor activity and a manageable safety profile in patients with relapsed or refractory T-cell lymphomas, including AITL. It is currently progressing through Phase II clinical development, with the company planning to initiate a Phase III study. In December 2025, Innate Pharma announced that Phase II PTCL trial data are anticipated by the end of 2026, while Phase III initiation and an accelerated approval submission are targeted for 2027.
Linperlisib (YY-20394/Linprixetine): Shanghai YingLi Pharmaceutical
Linperlisib is a selective PI3Kδ inhibitor administered orally once daily. Across multiple clinical studies involving patients with relapsed or refractory peripheral T-cell lymphoma, the therapy has demonstrated favorable safety, durable anti-tumor activity, and encouraging survival outcomes. It is currently one of the leading investigational therapies for AITL. In April 2025, the US FDA cleared the company's pivotal Phase III clinical trial protocol following a successful End-of-Phase II meeting, with the global registration study scheduled to begin during Q2 2025.
Duvelisib (COPIKTRA): Secura Bio
Duvelisib (COPIKTRA) is an oral dual PI3K-δ and PI3K-γ inhibitor being developed for patients with relapsed or refractory peripheral T-cell lymphoma, including AITL. Clinical studies have demonstrated encouraging response rates together with a manageable safety profile. The therapy is currently being evaluated in the Phase III TERZO study, which uses progression-free survival (PFS) as its primary endpoint. In December 2025, Secura Bio confirmed that the Phase III trial remains on track for an interim data readout in early 2027 following patient enrollment initiated during 2025.
GFH009: GenFleet Therapeutics
GFH009 is another promising investigational therapy being evaluated as part of the emerging AITL pipeline. The therapy represents one of several novel targeted approaches expected to broaden future treatment options for patients with relapsed or refractory disease.
Discover more about therapies expected to transform the Angio-immunoblastic T-Cell Lymphoma (AITL) market @ Angio-immunoblastic T-Cell Lymphoma Treatment Landscape
Recent Developments in the Angio-immunoblastic T-Cell Lymphoma (AITL) Market
• In December 2025, Secura Bio announced that the Phase III TERZO study evaluating Duvelisib remains on track for an interim data readout in early 2027.
• In April 2025, Shanghai YingLi Pharmaceutical received US FDA clearance to initiate the pivotal Phase III trial evaluating Linperlisib in relapsed/refractory peripheral T-cell lymphoma.
• In December 2025, Innate Pharma announced that Phase II clinical data for Lacutamab are expected by the end of 2026.
• In May 2025, Innate Pharma announced plans to initiate a Phase III study of Lacutamab, with an accelerated regulatory submission anticipated in 2027.
What is Angio-immunoblastic T-Cell Lymphoma (AITL)?
Angio-immunoblastic T-Cell Lymphoma (AITL) is a rare, aggressive subtype of peripheral T-cell lymphoma (PTCL) characterized by systemic lymphadenopathy, constitutional symptoms, immune dysregulation, and complex genetic alterations. The disease typically presents with generalized lymph node enlargement, fever, skin rash, weight loss, hepatosplenomegaly, and autoimmune manifestations. Despite initial responses to chemotherapy, relapse rates remain high, emphasizing the need for novel targeted therapies capable of improving long-term clinical outcomes.
Angio-immunoblastic T-Cell Lymphoma (AITL) Epidemiology Segmentation
The DelveInsight report provides a comprehensive epidemiological assessment of Angio-immunoblastic T-Cell Lymphoma across the Seven Major Markets (7MM) during 2022-2036, segmented into:
• Total Incident Cases of Peripheral T-cell Lymphoma (PTCL)
• Total Incident Cases of Angio-immunoblastic T-Cell Lymphoma (AITL)
• CD30 Expression in AITL
• Stage-specific Incident Cases of AITL
• Line-wise Treated Cases of AITL across the United States, EU4 and the United Kingdom, and Japan.
Download the report to explore detailed epidemiology trends, emerging therapies, competitive intelligence, and commercial opportunities in the Angio-immunoblastic T-Cell Lymphoma (AITL) market:
https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Scope of the Angio-immunoblastic T-Cell Lymphoma (AITL) Market Report
• Study Period: 2022-2036
• Coverage: Seven Major Markets (7MM) - United States, Germany, France, Italy, Spain, the United Kingdom, and Japan
• Key Companies: Innate Pharma, Shanghai YingLi Pharmaceutical, Secura Bio, GenFleet Therapeutics, and others
• Current Therapies: ADCETRIS, BELEODAQ, EZHARMIA, FOLOTYN/DIFOLTA, ISTODAX, CHOP, CHOEP, stem cell transplantation
• Emerging Therapies: Lacutamab (IPH4102), Linperlisib (YY-20394/Linprixetine), Duvelisib (COPIKTRA), GFH009, and others
• Epidemiology Segmentation: Total incident PTCL cases, total incident AITL cases, CD30 expression, stage-specific incident cases, and line-wise treated cases
• Market Insights: Historical and forecasted market size, therapy uptake, pricing trends, analogue assessment, competitive landscape, SWOT analysis, unmet needs, and market forecasts through 2036
• Market Access: Country-specific reimbursement and Health Technology Assessment (HTA) landscape across the 7MM
• Additional Coverage: Patient journey, KOL perspectives, market dynamics, reimbursement strategies, analyst views, and competitive benchmarking.
To learn more about the Angio-immunoblastic T-Cell Lymphoma (AITL) market, epidemiology, and emerging treatment landscape, visit:
https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
• Angio-immunoblastic T-Cell Lymphoma (AITL) Market Report Introduction
• Angio-immunoblastic T-Cell Lymphoma (AITL) Market Executive Summary
• Angio-immunoblastic T-Cell Lymphoma (AITL) Market Overview
• Angio-immunoblastic T-Cell Lymphoma (AITL) Disease Background and Overview
• Angio-immunoblastic T-Cell Lymphoma (AITL) Etiology and Pathogenesis
• Angio-immunoblastic T-Cell Lymphoma (AITL) Diagnosis and Treatment Guidelines
• Angio-immunoblastic T-Cell Lymphoma (AITL) Epidemiology and Market Methodology
• Angio-immunoblastic T-Cell Lymphoma (AITL) Epidemiology Analysis
• Angio-immunoblastic T-Cell Lymphoma (AITL) Patient Population Analysis
• Angio-immunoblastic T-Cell Lymphoma (AITL) Current Treatment Landscape
• Angio-immunoblastic T-Cell Lymphoma (AITL) Emerging Therapies
• Angio-immunoblastic T-Cell Lymphoma (AITL) Market Dynamics
• Angio-immunoblastic T-Cell Lymphoma (AITL) Market Size Analysis (2022-2036)
• Angio-immunoblastic T-Cell Lymphoma (AITL) Drug Uptake Analysis
• Angio-immunoblastic T-Cell Lymphoma (AITL) Pricing Trends and Analogue Assessment
• Angio-immunoblastic T-Cell Lymphoma (AITL) Competitive Landscape
• Angio-immunoblastic T-Cell Lymphoma (AITL) Key Companies
• Angio-immunoblastic T-Cell Lymphoma (AITL) Key Therapies
• Angio-immunoblastic T-Cell Lymphoma (AITL) Market Access and Reimbursement
• Angio-immunoblastic T-Cell Lymphoma (AITL) Key Opinion Leader (KOL) Views
• Angio-immunoblastic T-Cell Lymphoma (AITL) Patient Journey
• Angio-immunoblastic T-Cell Lymphoma (AITL) SWOT Analysis
• Angio-immunoblastic T-Cell Lymphoma (AITL) Unmet Needs
• Market Drivers and Barriers
• Future Perspectives
• Analyst Views
• Appendix
Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Angio-immunoblastic T-Cell Lymphoma (AITL) Market Expected to Witness Significant Growth Through 2036, Driven by Advancing Targeted Therapies, Improving Diagnosis, and Expanding Treatment Landscape | DelveInsight here
News-ID: 4596445 • Views: …
More Releases from DelveInsight Business Research LLP
The Global Skin Grafting Devices Market Size is projected to grow at a CAGR of 7 …
The Skin Grafting Devices market is estimated to grow at a CAGR of 7.31% during the forecast period from 2025 to 2032, supported by rising burn and traumatic injury rates, a growing chronic wound burden, and continued technological advancement in dermatomes and grafting systems.
DelveInsight's Skin Grafting Devices Market Insights Report 2032 provides current and forecast market analysis, individual leading Skin Grafting Devices companies' market shares, challenges, Skin Grafting Devices Market…
The Global Pediatric Neurology Devices Market Size is projected to grow at a CAG …
The Pediatric Neurology Devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2024 to 2030, driven by the rising prevalence of pediatric neurological disorders and growing demand for minimally invasive treatment options.
DelveInsight's Pediatric Neurology Devices Market Insights Report 2030 provides current and forecast market analysis, individual leading Pediatric Neurology Devices companies' market shares, challenges, Pediatric Neurology Devices Market Drivers, barriers, trends, and key…
The Global Brain Monitoring Devices Market Size is projected to grow at a CAGR o …
The Brain Monitoring Devices market was valued at USD 5.89 billion in 2024 and is projected to reach USD 9.13 billion by 2032. Growth is driven by increasing instances of neurological disorders such as multiple sclerosis, epilepsy, and dementia, coupled with increasing awareness of these disorders and rising product developmental activities.
DelveInsight's Brain Monitoring Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Brain Monitoring Devices…
The Global Neurovascular Devices Market Size is projected to grow at a CAGR of 8 …
The Neurovascular Devices market is estimated at USD 3,904.74 million in 2025 and is projected to reach USD 8,044.66 million by 2034. Growth is anchored in the rising prevalence of stroke, cerebral aneurysms, and other cerebrovascular diseases, alongside continuous technological advancement in minimally invasive devices.
DelveInsight's Neurovascular Devices Market Insights Report 2034 provides the current and forecast market analysis, individual leading Neurovascular Devices companies' market shares, challenges, Neurovascular Devices Market Drivers,…
More Releases for AITL
Angioimmunoblastic T-Cell Lymphoma (AITL) Market Growing at a CAGR of around 6.8 …
Angioimmunoblastic T-Cell Lymphoma (AITL) Market
The Angioimmunoblastic T-Cell Lymphoma (AITL) Market was valued at ~USD 610 million in 2024 and is projected to reach ~USD 1.18 billion by 2034, growing at a CAGR of around 6.8%. Growth is driven by rising diagnosis of peripheral T-cell lymphomas, increasing use of combination chemotherapy, and expanding adoption of targeted and immunotherapy-based regimens.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71271
Key Market Drivers
• Rising incidence…
Angioimmunoblastic T-Cell Lymphoma Market Outlook 2025-2034, Trends, Pipeline De …
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL) that primarily affects T-cells. It is characterized by a combination of immune system dysfunction, abnormal lymphocyte growth, and a highly variable clinical presentation, which makes diagnosis and treatment particularly challenging. AITL often leads to widespread disease dissemination and a poor prognosis, with many patients experiencing resistance to conventional therapies like chemotherapy and radiotherapy.
Download Full PDF Sample…
Angioimmunoblastic T-Cell Lymphoma Pipeline Insight 2025: Targeted Immunotherapi …
The therapeutic pipeline for angioimmunoblastic T-cell lymphoma (AITL) is growing, driven by the need to address its aggressive nature and poor prognosis. Current treatments, such as CHOP-like chemotherapy and stem cell transplants, often result in high relapse rates and limited long-term responses. In response, R&D is increasingly focused on targeting key molecular drivers like T-cell receptor signaling, epigenetic changes, and the tumor microenvironment.
DelveInsight's "Angioimmunoblastic T-Cell Lymphoma - Pipeline Insight, 2025…
Angioimmunoblastic T-Cell Lymphoma Market Forecast to Expand by 2034 Amid Rising …
Angioimmunoblastic T-Cell Lymphoma (AITL) is a rare and aggressive subtype of peripheral T-cell lymphoma (PTCL), characterized by systemic symptoms, immune dysregulation, and frequent genetic mutations such as TET2, DNMT3A, and RHOA. The disease typically affects older adults and presents with generalized lymphadenopathy, skin rashes, and constitutional symptoms, contributing to a poor prognosis and high relapse rates.
DelveInsight's latest report, "Angioimmunoblastic T-Cell Lymphoma (AITL) - Market Insight, Epidemiology, and Market Forecast -…
First International Accredited Independent Testing Laboratory Approved by CRRC
The Cool Roof Rating Council (CRRC) is pleased to announce the approval of the first CRRC Accredited Independent Testing Laboratory (AITL) that is located outside of the United States of America. On April 7, 2025, the Centre for Advanced Research in Building Science and Energy (CARBSE) at the CEPT University Research and Development Foundation (CRDF) received approval to perform third-party testing for the CRRC Roof Product Rating Program, Roof Rapid…
Angio-immunoblastic T-cell Lymphoma Market to Witness Growth by 2032 | Major pla …
DelveInsight's "Angio-immunoblastic T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Angio-immunoblastic T-cell Lymphoma, historical and forecasted epidemiology as well as the Angio-immunoblastic T-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Angio-immunoblastic T-cell Lymphoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted…
